Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma
Recruiting · NCT06044051 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Rouen
View the official record on ClinicalTrials.gov →Interventions studied
Blood sampleExpectorationNasopharyngeal swab
What this trial is about
Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment. Exploring and understanding these data is to improve patient care and discover new therapeutic targets. The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.
Who can take part
Age range
Up to 24 Months
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Infants less than 24 months old
- Follow-up by a pneumo-pediatrician for severe asthma in infants
- Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009)
- Parent informed of the research and having signed consent
Exclusion criteria
- Prematurity \<32 WA
- Congenital heart disease with significant left to right shunt
- Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans)
- Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization)
- Refusal of bronchial fibroscopy
Where it is running
1 location listed.
- Rouen University Hospital - Rouen, France